Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Allogene Therapeutics, Inc. (ALLO) vs Valneva SE Sponsored ADR (VALN)

Allogene Therapeutics, Inc. and Valneva SE Sponsored ADR are both Biotechnology companies. Allogene Therapeutics, Inc. and Valneva SE Sponsored ADR are of similar size ($594.2M and $589.8M). Allogene Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Valneva SE Sponsored ADR trades at 65.3×. Allogene Therapeutics, Inc. grew revenue faster over the last twelve months: 7,613.1% against −53.2%. Valneva SE Sponsored ADR has the higher net margin (−12.0% vs −3,517.4%) and the higher return on invested capital (0.00% vs −108.8%). Across the 17 metrics below, Valneva SE Sponsored ADR leads on 11 and Allogene Therapeutics, Inc. on 6.

Valuation

Metric ALLO VALN Biotechnology median
P/E n/m 65.32 7.88
P/S 115.35 3.33 11.47
P/B 1.24 5.80 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 46.45 0.74
EV/Sales 44.66 3.78 10.73
Earnings yield (40.61%) 1.53% (28.84%)
Free cash flow yield (18.90%) (10.77%) (23.03%)

Profitability

Metric ALLO VALN Biotechnology median
Gross margin 100.00% 38.28% 65.16%
Operating margin (3,832.45%) 13.56% 0.00%
Net margin (3,517.41%) (12.01%) 0.00%
Free cash flow margin (2,180.62%) 0.00% 0.00%
Return on equity (42.39%) 0.00% (57.72%)
Return on assets (32.43%) 0.00% (49.22%)
Return on invested capital (108.81%) 0.00% 0.00%

Growth

Metric ALLO VALN Biotechnology median
Revenue growth (TTM) 7,613.11% (53.16%) 5.64%
EPS growth (last fiscal year) 34.09% (805.88%) —
Revenue growth, 5-year CAGR — 9.41% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALLO VALN Biotechnology median
Debt to equity 0.00 2.27 0.00
Current ratio 10.72 2.16 4.73
Net debt to EBITDA 1.24 (1.15) 0.96

Dividend

Metric ALLO VALN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ALLO VALN Biotechnology median
Market cap 594.24m 589.78m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack